New NATAP Fall 43-page 2004 Newsletter, 12 pgs on entry inhibitors

[Guest guest]

NATAP - www.natap.org

New NATAP HIV Fall 43-page 2004 Newsletter

to order print copies contact NATAP at 1-888-26-natap

http://www.natap.org/newsletters.htm

Tipranavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1

HIV Entry Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1

CCR5 Inhibitors: GW873140 . . . . . . . . . . . . . . . . . . . . . . . .4

Entry Inhibitor Drugs in Human Studies . . . . . . . . . . . . . . . 4

UK-427,857 CCR5 Inhibitor . . . . . . . . . . . . . . . . . . . . . . . . 7

Schering D 690 CCR5 Inhibitor; TNX-355 . . . . . . . . . . . . . . ..9

Attachment Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . .11

Fuzeon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. .12

New HIV Antiretroviral Drugs in Development . . . . . . . . . .15

TMC-125 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15

TMC-114 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..15

Reverset . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16

HIV Maturation Inhibitor PA-457 . . . . . . . . . . . . . . . . . . ..17

SPD754 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .17

GW695634 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .18

Double PI Regimens: Reyataz/ritonavir . . . . . . . . . . . . . . .18

908/Ritonavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..22

Saquinavir/ritonavir . . . . . . . . . . . . . . . . . . . . . . . . . . . .27

Kaletra Report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Sustiva . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31

Triple PI Regimins . . . . . . . . . . . . . . . . . . . . . . . . . . . . .32

ART Hepatotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33

6th Lipodystrophy Workshop: heart disease, lipoatrophy . ...34

Insulin Resistance/Diabetes and HIV; Aging & HIV . . . . . . ...35

Reyataz & Glucose Metabolism . . . . . . . . . . . . . . . . . . .. .37

Trizivir + Tenofovir Compared to Combivir + Efavirenz . . . . .38

FDAApproves Two Once Daily 1 Pill New Nuke Regimens ....39

Tenofovir+ FTC Once Daily Compared to w/Combivir . . . .. .39

HIV Superinfection & Response to HAART . . . . . . . . . . . ...40

HIV Drug Resistance Found in 1 of 7 Treatment Naives . . ...41

Transmitted HIV Drug Resistance & Response to HAART . ....41

Depression, HAART & Women . . . . . . . . . . . . . . . . . . .. . .42

Prevalence & Late Diagnosis of HIV in Black Men in NYC ......42

Safety & Tolerabiltiy of Vaginal Tenofovir-Microbicide . . . ....43

The articles in this newsletter report the latest information from studies presented at these leading medical conferences held in 2004:

o CROI- 11th Annual Conference on Retroviruses & Opportunistic Infections (Feb 2004)

o 10th International AIDS Conference (Bangkok, July 2004)

o Lipodystropohy Workshop- 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV

o ICAAC- 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC, October 2004)

o Glasgow- 7th International Congress on Drug Therapy in HIV Infection (Glasgow, November 2004)

o XIII International HIV Drug Resistance Workshop (Canary Islands, June 2004)